Kamna Nanda
Kamna Nanda has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Abhijit Ray
3 shared publicationsMou Chatterjee
Department of Pharmacology, Ranbaxy Research laboratories, Gurgaon, Haryana, India
3 shared publicationsSuman Gupta
2 shared publications- Abhijit Ray
Department of Pharmacology, Ranbaxy Research Laboratories, Plot No.20, Sector 18, Udyog Vihar Industrial Area, Gurgaon-122001 (Haryana), India
1 shared publication Anita Chugh
1 shared publicationAtul Tiwar
Department of Pharmacology, Ranbaxy Research laboratories, Gurgaon, Haryana, India
1 shared publication
Latest Publications
- 1 April 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 607 (1-3) , 213-219
RBx 6198: A novel α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia
- 1 April 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 607 (1-3) , 213-219
RBx 6198: A novel α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia
- 18 March 2009
- Published by Wiley in Biotechnology Journal
- Vol. 4 (3) , 417-422
Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter
In this study we test whether functional screening of compounds to adrenergic G protein‐coupled receptors (GPCRs) would provide data that correlated significantly with radiolabeled binding data, thereby permitting researchers to replace expensive radioligand‐binding experiments with non‐radioactive screening. An increase in intracellular calcium levels represents an important second messenger signal for several recombinant GPCRs. In this study, we describe the affinities of three alpha adrenoceptor antagonists (terazosin, tamsulosin and alfuzosin), determined by monitoring the changes in intracellular calcium levels and comparing them with their radioligand‐binding affinities. In addition to determining the functional affinities of the three alpha adrenoceptor antagonists, we evaluate their binding at two alpha adrenoceptor subtypes and optimized the assay for high‐throughput screening.
- 18 March 2009
- Published by Wiley in Biotechnology Journal
- Vol. 4 (3) , 417-422
Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter
In this study we test whether functional screening of compounds to adrenergic G protein‐coupled receptors (GPCRs) would provide data that correlated significantly with radiolabeled binding data, thereby permitting researchers to replace expensive radioligand‐binding experiments with non‐radioactive screening. An increase in intracellular calcium levels represents an important second messenger signal for several recombinant GPCRs. In this study, we describe the affinities of three alpha adrenoceptor antagonists (terazosin, tamsulosin and alfuzosin), determined by monitoring the changes in intracellular calcium levels and comparing them with their radioligand‐binding affinities. In addition to determining the functional affinities of the three alpha adrenoceptor antagonists, we evaluate their binding at two alpha adrenoceptor subtypes and optimized the assay for high‐throughput screening.
- 17 October 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (9-10) , 1276-1279
Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system
Phosphodiesterases (PDEs) hydrolyze cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. Inhibitors of PDEs allow the elevation of cAMP and cGMP, which leads to a variety of cellular effects including airway smooth muscle relaxation and inhibition of cellular inflammation or of immune responses. PDE4 inhibitors specifically prevent the hydrolysis of cAMP. We have validated the manually developed reporter gene assay in a high‐throughput screening format that allows for fast and cost‐effective identification of potential inhibitors of PDE4 isozymes. The assay is sensitive and robust, with a Z' value of >0.5. The assay is also amenable to 384‐well format.
- 17 October 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (9-10) , 1276-1279
Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system
Phosphodiesterases (PDEs) hydrolyze cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. Inhibitors of PDEs allow the elevation of cAMP and cGMP, which leads to a variety of cellular effects including airway smooth muscle relaxation and inhibition of cellular inflammation or of immune responses. PDE4 inhibitors specifically prevent the hydrolysis of cAMP. We have validated the manually developed reporter gene assay in a high‐throughput screening format that allows for fast and cost‐effective identification of potential inhibitors of PDE4 isozymes. The assay is sensitive and robust, with a Z' value of >0.5. The assay is also amenable to 384‐well format.
- 1 September 2008
- Published by Elsevier in Analytical Biochemistry
- Vol. 380 (1) , 143-145
An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors
- 1 September 2008
- Published by Elsevier in Analytical Biochemistry
- Vol. 380 (1) , 143-145
An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors